Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
| ▸ | FAAH | O00519 | 1/20 | 0.44 |
| ▸ | TSHR | P16473 | 1/20 | 0.44 |
| ▸ | CCR1 | P32246 | 1/20 | 0.43 |
| ▸ | DRD2 | P14416 | 3/20 | 0.43 |
| ▸ | DRD4 | P21917 | 1/20 | 0.43 |
| ▸ | DRD3 | P35462 | 1/20 | 0.43 |
| ▸ | S1PR2 | O95136 | 6/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5445764 | 0.90 | FAAH (0.45) | SMN1; SMN2FAAHDRD2LMNA | |
| SCHEMBL5442739 | 0.89 | FAAH (0.57) | SMN1; SMN2FAAHCCR1DRD2DRD4 | |
| SCHEMBL5447955 | 0.88 | FAAH (0.44) | SMN1; SMN2FAAHTSHRCCR1DRD2 | |
| SCHEMBL5447927 | 0.88 | SMN1; SMN2 (0.45) | SMN1; SMN2FAAHTSHRCCR1LMNA | |
| SCHEMBL5445830 | 0.87 | FAAH (0.46) | SMN1; SMN2FAAHCCR1DRD2DRD4 | |
| SCHEMBL5452097 | 0.86 | GAA (0.46) | SMN1; SMN2FAAHLMNA | |
| SCHEMBL5445795 | 0.86 | KDM4E (0.42) | FAAHPOLB | |
| SCHEMBL5443508 | 0.85 | FAAH (0.46) | SMN1; SMN2FAAHCCR1DRD4S1PR2 | |
| SCHEMBL5442748 | 0.85 | FAAH (0.47) | SMN1; SMN2FAAHCCR1DRD2DRD3 | |
| SCHEMBL5452293 | 0.84 | FAAH (0.50) | SMN1; SMN2FAAHCCR1DRD2DRD3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070021405-A1 | ARYL- AND HETEROARYLPIPERIDINECARBOXYLATE-DERIVATIVES METHODS FOR THEIR PREPARATION AND USE THEREOF AS FATTY ACID AMIDO HYDROLASE ENZYME INHIBITORS | SANOFI-AVENTIS (FR) | 2007-01-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070021405-A1 | ARYL- AND HETEROARYLPIPERIDINECARBOXYLATE-DERIVATIVES METHODS FOR THEIR PREPARATION AND USE THEREOF AS FATTY ACID AMIDO HYDROLASE ENZYME INHIBITORS | FAAH, FAAH2, HRH2 | SMN1; SMN2 1268/4885FAAH 1/4885TSHR 855/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.